Inventor · disambiguated record
Jacques Van Snick
Also filed as: VAN SNICK JACQUES
25 granted patents·7 pending applications·282 citations·filing 1988–2022
96Inventor score
Files withLUDWIG INST CANCER RES16LUDWIG INST FOR CANCER RES LTD6MEDIMMUNE INC2UNIV CATHOLIQUE LOUVAIN2VAN SNICK JACQUES2
Top patents by PatentIndex Score
32 records- 0196US9518112B2TGF-β1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2013·Granted Dec 13, 2016·24 cites·20 claims
- 0293US11957751B2TGF-β1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2021·Granted Apr 16, 2024·2 cites·29 claims
- 0392US10947303B2TGF-ß1 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2018·Granted Mar 16, 2021·4 cites·14 claims
- 0487US10035851B2TGF-β1 specific antibodies and methods and uses thereofVAN SNICK JACQUES·Filed 2016·Granted Jul 31, 2018·4 cites·12 claims
- 0584US7371383B2Recombinant anti-interleukin-9 antibodiesMEDIMMUNE INC·Filed 2003·Granted May 13, 2008·21 cites·44 claims
- 0681US12221477B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2022·Granted Feb 11, 2025·0 cites·36 claims
- 0777US10723793B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2016·Granted Jul 28, 2020·1 cites·18 claims
- 0877US6645486B1Method of treatment with IL-9 conjugateLUDWIG INST CANCER RES·Filed 2000·Granted Nov 11, 2003·8 cites·11 claims
- 0974US5246701AMethod for inhibiting production of IgE by using IL-9 inhibitorsLUDWIG INST CANCER RES·Filed 1991·Granted Sep 21, 1993·38 cites·8 claims
- 1074US5157112AAntibodies immunoreactive with the T-cell growth factor, P40LUDWIG INST CANCER RES·Filed 1989·Granted Oct 20, 1992·27 cites·6 claims
- 1173US5208218AT cell growth factor glycoproteinsLUDWIG INST CANCER RES·Filed 1988·Granted May 4, 1993·27 cites·6 claims
- 1272US11485780B2TGF-β3 specific antibodies and methods and uses thereofLUDWIG INST FOR CANCER RES LTD·Filed 2020·Granted Nov 1, 2022·0 cites·16 claims
- 1372US5116951ASubstantially pure interleukin-9 receptor and uses thereofLUDWIG INST CANCER RES·Filed 1990·Granted May 26, 1992·34 cites·4 claims
- 1465US5132109AMethod for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereofLUDWIG INST CANCER RES·Filed 1990·Granted Jul 21, 1992·23 cites·2 claims
- 1564US6716809B1Mage-A3 peptides presented by HLA class moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Apr 6, 2004·15 cites·14 claims
- 1663US7094396B2Method for making cytokine specific antibodies and uses thereofLUDWIG INSTITIUTE FOR CANCER R·Filed 2003·Granted Aug 22, 2006·1 cites·19 claims
- 1762US5180678AUses of substantially pure interleukin-9 receptorLUDWIG INST CANCER RES·Filed 1992·Granted Jan 19, 1993·22 cites·6 claims
- 1855US5164317AMethod for enhanced growth and proliferation of mast cellsLUDWIG INST CANCER RES·Filed 1991·Granted Nov 17, 1992·20 cites·8 claims
- 1955US2008299134A1Recombinant Anti-Interleukin-9 AntibodiesMEDIMMUNE INC·Filed 2008·Application pending·0 cites
- 2048US2003091533A1Regulation of mononuclear phagocyte stimulationFiled 2002·Application pending·0 cites
- 2147US2008299073A1Method For Treatment Or Prophylaxis Of An Infection Using Either An Antibody Which Binds To IL-9 Or An Agent Which Stimulates Production Of Autoantibodies To Interleukin-9VAN SNICK JACQUES·Filed 2005·Application pending·0 cites
- 2247US2007048261A1Vaccine comprising il-12 or il-23 for treatment of autoimmune diseasesGLAXOSMITHKLINE BIOLOG SA·Filed 2004·Application pending·0 cites
- 2345US2019160177A1Method for increasing the bioavailability of inhaled compoundsUNIV CATHOLIQUE LOUVAIN·Filed 2019·Application pending·0 cites
- 2443US7157091B1MAGE-A1 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Jan 2, 2007·4 cites·8 claims
- 2543US6558660B2Method for regulating IL-10 with IL-9, and applications thereofLUDWIG INST CANCER RES·Filed 2001·Granted May 6, 2003·0 cites·6 claims
- 2642US6328955B1Method for regulating IL-10 with IL-9, and applications thereofLUDWIG INST CANCER RES·Filed 2000·Granted Dec 11, 2001·0 cites·14 claims
- 2742US2002164301A1Methods for inhibiting atherosclerotic plaque formationFiled 2002·Application pending·0 cites
- 2837US5962269AMethods for producing antibodies which specifically bind to interleukin-9 receptorLUDWIG INST CANCER RES·Filed 1995·Granted Oct 5, 1999·3 cites·9 claims
- 2937US5789237ANucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptorLUDWIG INST CANCER RES·Filed 1993·Granted Aug 4, 1998·4 cites·23 claims
- 3035US2016331839A1Method for increasing the bioavailability of inhaled compoundsUNIV CATHOLIQUE LOUVAIN·Filed 2015·Application pending·0 cites
- 3131US5750377AProcess for preparing mammalian T cell growth factor P40LUDWIG INST CANCER RES·Filed 1995·Granted May 12, 1998·0 cites·8 claims
- 3231US5587302AT cell growth factorLUDWIG INST CANCER RES·Filed 1990·Granted Dec 24, 1996·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →